Hong Kong Med J 2022 Oct;28(5):413 | Epub 21 Sep 2022
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
Vitamin D supplementation to prevent COVID-19 in older people
Timothy Kwok
Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong
Corresponding author: Prof Timothy Kwok (tkwok@cuhk.edu.hk)
 Full paper in PDF
To the Editor—Since the review on the immune modulating effects of vitamin D in coronavirus disease 2019 (COVID-19) infection by Kaler et al1 last year, there has been an open-label trial showing positive effects of vitamin D supplementation in COVID-19 patients in Spain. Out of 838 COVID-19 in patients, 447 were routinely given calcifediol (25-hydroxycholecalciferol) 532 μg on admission, and 266 μg on day 3,7,15 and 30. The treatment group had very significantly lower rates of intensive care unit admission (4.5% vs 21%) and death (4.7% vs 15.9%).2 In contrast, two randomised trials of a single large dose of vitamin D3 on admission in moderate to severe COVID-19 patients have showed no significant benefits.3 The discrepant results may be due to differences in vitamin D formulations. As compared with vitamin D3, calcifediol does not require hydroxylation in liver which is often impaired in acute illness. Therefore, vitamin D supplementation should preferably be started before exposure to COVID-19. Older people who seldom go outside, especially those in old age homes, have high prevalence of vitamin D deficiency. Indeed, an expert group recommended routine use of vitamin D3 1000 units daily in old age homes.4 A randomised trial of vitamin D3 in older people showed that doses up to 2000 units daily for four months was very safe.5 In the midst of the pandemic, I recommend vitamin D3 2000 units once daily in homebound older people to prevent COVID-19 infection and its complications, especially those who are not fully vaccinated.
Author contributions
The author contributed to the Letter, approved the final version for publication, and takes responsibility for its accuracy and integrity.
Conflicts of interest
The author has disclosed no conflicts of interest.
This Letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
1. Kaler J, Hussain A, Azim D, Ali S, Nasim S. Optimising vitamin D levels in patients with COVID-19. Hong Kong Med J 2021;27:154-6.Crossref
2. Nogues X, Ovejero D, Pineda-Moncusí M, et al. Calcifediol treatment and COVID-19-related outcomes. J Clin Endocrinol Metab 2021;106:e4017-27. Crossref
3. Cannata-Andía JB, Díaz-Sottolano A, Díaz-Sottolano A, et al. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial. BMC Med 2022;20:83. Crossref
4. Rolland Y, de Souto Barreto P, Abellan Van Kan G, et al. Vitamin D supplementation in older adults: searching for specific guidelines in nursing homes. J Nutr Health Aging 2013;17:402-12. Crossref
5. Schwartz JB, Kane L, Bikle D. Response of vitamin D concentration to vitamin d3 administration in older adults without sun exposure: a randomized double-blind trial. J Am Geriatr Soc 2016;64:65-72. Crossref